Back to Results

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Kelly Maloney,  MD

Kelly Maloney, MD

Study ID

Protocol Number: 16-1970

More information available at ClinicalTrials.gov: NCT02723994

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers